A Coming Together
Sitting here, watching, is a merging or a coming together actually happening? Let's speculate.
Some are saying CytoDyn has removed HIV from its website. I don't know how to interpret this. Looking at the website, I see HIV. Here it is in amber on the Pipeline Page:
HIV still exists in the Pipeline
Max still sits 2nd on its Leadership Team, as SVP - Head of Clinical Development:
I still see Scott Hansen, PhD - Head of Research and Basic Science on the Leadership Team:
I do see a shortened version of Jonah Sacha's Bio, but he remains as head of CytoDyn's Scientific Advisory Board:
When it comes to HIV, what is CytoDyn's greatest advantage? The HIV CURE. CytoDyn is close to a cure in HIV. It is working on HIV-AAV, HIV-Triple Therapy, using HIV-PLS, employing LS mutations on the leronlimab molecule which extends its half life and permits the crossing of the placenta. HIV-LATCH is a stem cell HIV Cure being prepared now for (2) distinct Pilot Trials to happen this year in 2025.
The HIV CURE Front certainly is a battle ground which CytoDyn is ahead on and likely in the lead in, although, it hasn't yet won. But, win it must, if it is to have any part of HIV at all. The fact is that CytoDyn is way ahead, even in the lead, but that doesn't mean CytoDyn's arch nemesis doesn't want to interfere and disrupt. In fact, they could even desire to compete in the development of a complete HIV Cure.
However, any complete cure would put them out of business, while a leronlimab complete cure would put CytoDyn into business . They might want to develop any complete cure, solely to snuff CytoDyn out of the race for an HIV Cure.
As we have discussed only a few short months ago, especially when BG conversed with DJT of future plans and when the GF hired Lataillade as SVP to Head the Development of HIV Drugs at the same time as when Jacob Lalezari hired Max Lataillade as SVP to Head Clinical Development at CytoDyn. This gave us some suspicion that a coalition could be in formation. This was quickly followed up with a cool $966,600 grant sponsored to the NIH and to CytoDyn's own Jonah Sacha for the purpose of determining the means of HIV Reservoir formation. The consensus formed was that an arrangement could be in formation that would put the future development of the HIV CURE into the hands of a Consortium that could be in part funded by the GF, but utilizing the design experience of the scientists at ViiV and GSK, and managed under the auspices of Max Lataillade who reports to Jacob Lalezari, Bill Gates and to the CEO of GSK, Emma Walmsley.
Now, we see CytoDyn's website has modestly changed, but it still does speak of HIV and it has multiple papers still listed which do discuss HIV, while some other HIV information has been removed. To me, it makes sense that this final front in HIV, that is the HIV CURE, is important enough to protect and to insure that it too is not lost to the likes of the arch enemy.
That enemy has all the regular treatments in ART and HAART. They have PrEP, but they don't have HIV CURE. Right now, nobody has the Cure, but CytoDyn has multiple avenues, which it has already proven, but not yet in humans, only in macaques. LATCH though, has been proven in humans and again, (2) Pilot Trials are slated for later this year.
It is very important that the arch rival is left out of this race. They don't belong in this race. They have no desire for a cure. They have no interest in finding a cure, because if they get the Cure, they would shelve it anyway. They don't want to cure people, they want to sell their treatment medications forever. They don't want people cured of HIV. They want them sick forever, but treated forever. So, they do not belong in the race for the Cure.
They should not continue in any research for such a cure. All of it should be dismantled. I don't believe they would agree to dismantle. I would think somebody from the GF, GSK or ViiV would enforce the neutralization of their pursuit of the HIV Cure. It has to be neutralized or else they would rise up and attempt taking that indication.
CytoDyn certainly is mobilizing. Something recently has happened with regards to their website and ever since that $966,600 grant to NIH, Jonah's Bio has been somewhat diminished when it really should have been elevated. Something is going on in HIV and it may be due to a transference or to a licensing in accordance with the funders / sponsors of that grant, and with the other players who Max reports to.
How does CytoDyn play this HIV-CURE indication harder? CytoDyn does need to play with the big boys. They do need to play it on the level which it is played. But they do have the GF Head of HIV Drug Development, who was also SVP at ViiV and at GSK who is currently CytoDyn's Head of Clinical Development that is managing it all.
Have to ask, has Jacob Lalezari ever met Bill Gates? He probably should. Has he ever met RFK Jr? Has he ever met Jay Bhattacharya who is head of NIH? What about Emma Walmsley who is CEO of GSK? Has Jay ever spoken to her? He probably should meet all of these guys and gals. He needs to feed them all with what we have. He needs to be in their ear day in and day out. Or, does he leave this responsibility to Max? That may be the case. Maybe CytoDyn is trying to quietly dampen its obvious big mouth presence in HIV by offloading some of that into Max's lap?
What then would they talk about? HIV Cure for sure and the roles of each party involved. What part does the GF play, does GSK play, does ViiV play? What is CytoDyn's involvement other than supplying leronlimab and licensing? What part does the NIH play? and very importantly, how is G kept out? How is this kept very quiet? Are website changes necessary to fade us out of the lime light? How do we keep things going at full speed while minimizing what we are doing?
I think, so far, Jonah has done an incredible job in advancing the treatment of HIV using leronlimab and with Scott Hansen's help, has made great advancements in the overall development of long acting leronlimab which should be very instrumental in HIV PrEP. These variations of leronlimab do not effect leronlimab's function in any way, but its half life is dramatically extended. These medications then become usable towards other indications that require less frequent dosing, with longer durations of action.
For example, based on what we know right know, it could become possible to eradicate mTNBC with 3 or 4 treatments of long acting leronlimab, if a variation emerges in which each dose lasts 6 months. That would be 1.5-2 years of leronlimab delivered in only 3 or 4 injections spanned over 2 years. And this would be coming about as a result of the work of Scott Hansen.
The coming data that is soon to be revealed at ESMO shall have substantial implication. The possibility for partnership based on what is divulged at ESMO is high. Similarly, when Amarex was forced to turn over the mTNBC data, they also turned over any hidden aspects of the HIV-MDR data which was not properly included in the HIV-MDR BLA. If there is anything of note hidden in that data, then, assuredly, Max would have taken that to the GF, GSK and ViiV. Could/Would they resurrect the HIV-MDR BLA? Possibly, but it would be as a license of leronlimab issued by CytoDyn to the Consortium.
When it comes to MASH, CytoDyn is fighting no longer directly on the steatosis front. They have limited that fight to the fibrosis front only. Certainly leronlimab could be combined with another drug which does fight off hepatic steatosis, but it would be intended for the purpose of fighting off the hepatic fibrosis. CytoDyn is winning on this front because it was recently determined that leronlimab can fight off fibrosis of any etiology and in fact, a Pulmonary Fibrosis Pilot Trial is slated to begin. Leronlimab may now be considered for any kind of fibrosis including cardiac fibrosis and renal, as well as hepatic and pulmonary.
For good reason, leronlimab is being seriously considered for Stroke as it is a neurologic disease. There are very few medications even in the ball park that can play the neurologic game. That is why leronlimab is slated to begin its Alzheimer's Disease Pilot Trial and is probably already complete with its Glioblastoma Multiforme Murine Study. CytoDyn is confident in leronlimab's capacity to eradicate tumors that metastasize to the brain. CytoDyn is cornering the neurologic market, when it comes to eradicating neurologic inflammation. CytoDyn is pushing everyone out of the brain. Leronlimab safely crosses the blood brain barrier and is effective against neuro-inflammation. There are lot's of reasons why CytoDyn is staying inside the brain. That's another place it is refusing to leave.
Seems to be a slow go on the MSS mCRC front, but its start is about to commence. Nobody can treat MSS tumor types. Just leronlimab. G is using SC as a specialized chemotherapy against mTNBC, which is also a MSS tumor type. CytoDyn is planning on combining with chemo for MSS mCRC. I would tend to think that the same Consortium who is combining to license leronlimab for HIV CURE, would possibly do the same for leronlimab in mTNBC, but excluding ViiV. Heck, once MSS mCRC proves itself out, they'll come on board for that one too.
Ever hear the expression, "You are who you hang out with."? That means you can know somebody by who they associate with. We know where Max hung out. We know where he used to work for the past 10 years. We know where he still works. We know what he has accomplished. We know who these entities are. We know who they purport to support and what their mission statements are.
So CytoDyn is fighting on multiple fronts, but the team doing the fighting is a winning one and they have many fronts by which they can win. Remember the saying, "Birds of a feather, flock together." Just ponder on that.
No time to make any links.
Posted Apr 6, 2025, 2:26 PM UTC